Femasys (NASDAQ:FEMY – Get Free Report) will likely be posting its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect Femasys to post earnings of ($0.25) per share for the quarter.
Femasys Stock Down 2.5 %
FEMY stock opened at $1.56 on Tuesday. The company has a current ratio of 3.94, a quick ratio of 3.26 and a debt-to-equity ratio of 0.86. The firm has a 50-day moving average of $1.38 and a two-hundred day moving average of $1.22. Femasys has a 12 month low of $0.86 and a 12 month high of $1.84. The company has a market cap of $35.72 million, a price-to-earnings ratio of -1.93 and a beta of -2.85.
Analysts Set New Price Targets
Separately, HC Wainwright increased their price target on Femasys from $12.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday, March 19th.
About Femasys
Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.
Featured Stories
- Five stocks we like better than Femasys
- How to Calculate Inflation Rate
- Super Micro Stock: $7.2M Call Options Signal Big Upside Potential
- What Are Dividend Challengers?
- Top 3 Buy-and-Hold Stocks for 2025: Long-Term Winners to Watch
- Consumer Staples Stocks, Explained
- D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst?
Receive News & Ratings for Femasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Femasys and related companies with MarketBeat.com's FREE daily email newsletter.